

Title (en)
SYRINGE

Title (de)
SPRITZE

Title (fr)
SERINGUE

Publication
EP 2869813 B1 20181121 (EN)

Application
EP 13701276 A 20130125

Priority

- EP 12174860 A 20120703
- EP 12189649 A 20121023
- DE 202012011016 U 20121116
- AU 2012101677 A 20121116
- AU 2012101678 A 20121116
- DE 202012011260 U 20121123
- DE 202012011259 U 20121123
- EP 12195360 A 20121203
- DE 202013000688 U 20130123
- AU 2013100071 A 20130123
- AU 2013100070 A 20130123
- EP 2013051491 W 20130125
- EP 13701276 A 20130125

Abstract (en)
[origin: FR2983077A1] The syringe (1) has a stopper arranged within a body (2) such that a front surface of the stopper and the body define a variable volume chamber from which a fluid is expelled through an outlet of the body, and a backstop (6) including two finger projections. A plunger (4) comprises a plunger contact surface to contact the stopper such that the plunger forces the stopper towards an outlet end. The syringe is filled with a vascular endothelial growth factor (VEGF) antagonist fluid of about 0.15-0.175 ml containing a non-antibody VEGF antagonist aflibercept at a concentration of 40 mg/ml. The syringe comprises a syringe barrel filled with silicone oil of 100 microgram.

IPC 8 full level
A61K 9/00 (2006.01); **A61M 5/28** (2006.01); **A61M 5/31** (2006.01); **A61M 5/315** (2006.01)

CPC (source: EP IL KR US)
A61F 9/0008 (2013.01 - EP IL KR US); **A61K 9/0019** (2013.01 - EP IL US); **A61K 9/0048** (2013.01 - EP IL US);
A61K 38/179 (2013.01 - EP IL US); **A61M 5/002** (2013.01 - IL US); **A61M 5/178** (2013.01 - EP IL US); **A61M 5/28** (2013.01 - EP IL KR US);
A61M 5/31 (2013.01 - EP IL US); **A61M 5/3129** (2013.01 - KR); **A61M 5/315** (2013.01 - EP IL US); **A61M 5/31505** (2013.01 - EP IL KR US);
A61M 5/31513 (2013.01 - IL KR); **A61P 9/00** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 27/02** (2017.12 - EP);
A61P 35/00 (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **A61K 9/0019** (2013.01 - KR); **A61K 9/0048** (2013.01 - KR);
A61K 38/179 (2013.01 - KR); **A61M 5/31513** (2013.01 - EP US); **A61M 2005/3104** (2013.01 - EP IL US); **A61M 2005/3131** (2013.01 - KR);
A61M 2005/3139 (2013.01 - EP IL KR US); **A61M 2005/31508** (2013.01 - KR); **A61M 2210/0612** (2013.01 - KR)

Citation (examination)
SUMIT MAJUMDAR ET AL: "Evaluation of the effect of syringe surfaces on protein formulations", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 100, no. 7, 1 July 2011 (2011-07-01), pages 2563 - 2573, XP055059280, ISSN: 0022-3549, DOI: 10.1002/jps.22515

Citation (opposition)
Opponent : Dilg, Haeusler, Schindehmann Patentanwaltsgesellschaft mbH

- WO 9744068 A1 19971127 - SCHERING AG [DE], et al
- SCHOENKNECHT T P; ET AL: "REQUIREMENTS ON PRE-FILLABLE GLASS SYRINGES", AAPS NATIONAL BIOTECHNOLOGY CONFERENCE, 2007, XP003035654
- CHAN ET AL.: "SYRINGE SILICONIZATION PROCESS INVESTIGATION AND OPTIMIZATION", PDA J. PHARM. SCI. AND TECH., vol. 66, 2012, pages 136 - 150, XP003035655
- CLUNAS ET AL.: "RANIBIZUMAB PRE-FILLED SYRINGE: RECENTLY APPROVED INNOVATION IN THE EUROPEAN UNION WITH THE POTENTIAL TO REDUCE INFECTION RISK, IMPROVE DOSE ACCURACY, AND ENHANCE EFFICIENT TREATMENT ADMINISTRATION", 5TH WORLD CONGRESS ON CONTROVERSIES IN OPHTHALMOLOGY (COPHY), 20 March 2014 (2014-03-20), XP055638316, Retrieved from the Internet <URL:http://comtecmed.com/COPHY/2014/Uploads/Editor/Group%20A/17.pdf>
- MARKUS LANKERS: "The Relationship Between Silicone Layer Thickness, Free Silicone Oil and Protein Aggregation in Prefilled Syringes", AAPS NATIONAL BIOTECHNOLOGY CONFERENCE, 2010, pages 1 - 46, XP055186273
- BAKRI ET AL.: "Intravitreal Silicone Oil Droplets After Intravitreal Drug Injections", RETINA, vol. 28, no. 7, 2008, pages 996 - 1001, XP055186525
- MARION DASSINGER ET AL.: "Rote Liste® 2009", 2009, ROTE LISTE® SERVICE GMBH, Frankfurt/Main, article "67 273 Lucentis® 10mg/ml Injektionslösung", XP055638334
- "789- Particulate Matter in Ophthalmic Solutions", U. S. PHARMACOPEIA, Retrieved from the Internet <URL:http://ftp.uspbpep.com/v29240/usp29nf24s0_c789.html>

Opponent : Hoffmann Eitle

- EP 12174860 A 20120703
- EP 12189649 A 20121023
- DE 202012011016 U 20121116
- AU 2012101677 A 20121116
- AU 2012101678 A 20121116
- DE 202012011260 U 20121123
- DE 202012011259 U 20121123
- EP 12195360 A 20121203
- DE 202013000688 U 20130123
- AU 2013100071 A 20130123
- AU 2013100070 A 20130123
- WO 2014005728 A1 20140109 - NOVARTIS AG [CH], et al

- EP 2869813 A1 20150513 - NOVARTIS AG [CH]
- US 4184593 A 19800122 - DORR PAUL E [DE]
- US D430015 S 20000829 - HIMBERT HANS [SE], et al
- WO 9744068 A1 19971127 - SCHERING AG [DE], et al
- WO 2011006877 A1 20110120 - NOVARTIS AG [CH], et al
- REGENERON PHARMACEUTICALS, INC.,: "Aflibercept injection for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD)", DIVISION OF TRANSPLANT AND OPHTHALMOLOGY PRODUCTS ADVISORY COMMITTEE MEETING BRIEFING PACKAGE, pages 1 - 70
- ANONYMOUS: "PRODUCT INFORMATION EYLEA® aflibercept (rch)", AUSTRALIAN REGISTER OF THERAPEUTIC GOODS, 7 March 2012 (2012-03-07), pages 1 - 18, XP055642472
- "Product Information - for publication (Replacement)", THERAPEUTIC GOODS ADMINISTRATION, 6 June 2012 (2012-06-06), Retrieved from the Internet <URL:https://www.ebs.tga.gov.au/ebs/picmi/picmi.nsf/0/CA2576320083AA90CA2579BC001671F3>
- ANONYMOUS: "The United States Pharmacopeia USP 31. National Formulary NF 26", PHYSICAL TESTS/ (789) PARTICULATE MATTER IN OPHTHALMIC SOLUTIONS, vol. 1, 1 May 2008 (2008-05-01), pages 2p, 313 - 314, XP055642492
- ANONYMOUS: "Vorgefüllte Spritzen Teil 4: Spritzenzylinder aus Glas für Injektionspräparate", DEUTSCHE NORM DIN ISO 11040-4, August 1996 (1996-08-01), pages 1 - 5, XP055642494
- ANONYMOUS: "Prefilled syringes- Part 6 : Plastic barrels for injectables", INTERNATIONAL STANDARD : ISO 11040-6: 2012 (E), 1 April 2012 (2012-04-01), pages ii-iv, 1 - 10, XP055642502
- ANONYMOUS: "Sterile Einmalspritzen für medizinische Zwecke Teil 1: Spritzen zum manuellen Gebrauch", DEUTSCHE NORM DIN EN ISO 7886-1, October 1997 (1997-10-01), pages 1 - 19, XP055493706
- "Ph.Eur. 7. Ausgabe Grundwerk", 2011, article "3.2.8 Sterile Einmalspritzen aus Kunststoff", pages: 522 - 523, XP055642513
- ANONYMOUS: "Particle Counting in Injectable Solutions 2007 Updates", PARTICLE MEASURING SYSTEMS, INC., 2007, pages 6pp, XP055642519
- BAKRI ET AL.: "Intravitreal silicone oil droplets after intravitreal drug injections", RETINA, vol. 28, no. 7, July 2008 (2008-07-01), pages 996 - 1001, XP055186525
- FRANK BÖTTGER: "More than Filling. New Developments in Siliconization and Silicone Layer Analytics", BIO PRODUCTION FORUM - FILL AND FINISH FOR BIOPHARMACEUTICALS, 15 June 2010 (2010-06-15) - 17 June 2010 (2010-06-17), pages 1 - 43, XP055642524
- ANONYMOUS: "HIGHLIGHTS OF PRESCRIBING INFORMATION- LUCENTIS™ (ranibizumab injection)", GENENTECH, INC., 2006, pages 1 - 7, XP055642530, Retrieved from the Internet <URL:https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/1251561b1.pdf>
- ROCHE: "FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema", EUROPEAN PHARMACEUTICAL REVIEW, 13 August 2012 (2012-08-13), pages 1 - 7, XP055544843, Retrieved from the Internet <URL:https://www.europeanpharmaceuticalreview.com/news/14197/fda-approves-lucentis-ranibizumab-injection-for-treatment-of-diabetic-macular-edema/>
- CLIFF MINTZ: "Prefilled Syringes: The Next "Big Thing"", BIOPROCESS ONLINE, 30 August 2012 (2012-08-30), XP002788671
- BRUNO REUTER, CLAUDIA PETERSEN: "Syringe Siliconization Trends, methods, analysis procedures", TECHNOPHARM, vol. 2, no. 4, 2012, pages 238 - 244, XP002725465
- BADKAR ET AL.: "Development of Biotechnology Products in Pre-filled Syringes: Technical Considerations and Approaches", AAPS PHARMSCITECH, vol. 12, no. 2, June 2011 (2011-06-01), pages 564 - 572, XP019925550
- "between", CAMBRIDGE DICTIONARY, Retrieved from the Internet <URL:https://dictionary.cambridge.org/dictionary/english/between>
- "between", OXFORD DICTIONARY, Retrieved from the Internet <URL:https://en.oxforddictionaries.com/definition/between>
- FUNKE ET AL.: "Analysis of thin baked-on silicone layers by FTIR and 3D- Laser Scanning Microscopy", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 96, 2015, pages 304 - 313, XP055642550

Cited by

US11439758B2; US11433186B2; US10905786B2; US10918754B2; EP2869813B1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

DE 202013000688 U1 20130305; AR 090059 A1 20141015; AU 2013201624 A1 20140123; BR 112014032990 A2 20180306; BR 112014032990 B1 20220104; BR 122020020290 B1 20220405; CA 2803566 A1 20140103; CH 706741 A2 20140115; CH 706741 B1 20140214; CL 2014003619 A1 20151002; CN 104427972 A 20150318; CN 110115657 A 20190813; CN 111249062 A 20200609; CN 112972828 A 20210618; CO 7151483 A2 20141229; CY 1121497 T1 20200529; CY 1124431 T1 20220722; DK 2869813 T3 20190318; DK 3381444 T3 20210809; DK 3656373 T3 20220516; DK 3685826 T3 20220214; EA 031583 B1 20190131; EA 201590139 A1 20150730; EC SP15004005 A 20181031; EP 2869813 A1 20150513; EP 2869813 B1 20181121; EP 3381444 A1 20181003; EP 3381444 B1 20210519; EP 3470058 A1 20190417; EP 3656373 A1 20200527; EP 3656373 B1 20220216; EP 3685826 A1 20200729; EP 3685826 B1 20211103; ES 2712152 T3 20190509; ES 2882254 T3 20211201; ES 2906812 T3 20220420; ES 2912848 T3 20220530; FR 2983077 A1 20130531; FR 2983077 B1 20180914; GT 201400300 A 20151015; HK 1188404 A1 20140502; HR P20190300 T1 20190405; HR P20211216 T1 20211029; HR P20220083 T1 20220415; HR P20220535 T1 20220708; HU E042652 T2 20190729; HU E055227 T2 20211129; HU E057746 T2 20220628; IL 236296 A0 20150226; IL 36296 B 20200430; IL 272915 A 20200430; IL 272915 B 20210228; JO 3655 B1 20200827; JO P20200175 A1 20170616; JP 2014028114 A 20140213; JP 2014087678 A 20140515; JP 5744927 B2 20150708; JP 6313038 B2 20180418; KR 102092427 B1 20200417; KR 102299177 B1 20210908; KR 102341670 B1 20211222; KR 102395557 B1 20220509; KR 102443606 B1 20220914; KR 102487296 B1 20230113; KR 20150030216 A 20150319; KR 20200029611 A 20200318; KR 20210113413 A 20210915; KR 20210156865 A 20211227; KR 20220062681 A 20220517; KR 20220130821 A 20220927; KR 20230013282 A 20230126; LT 2869813 T 20190312; LT 3381444 T 20210825; LT 3656373 T 20220510; LT 3685826 T 20220210; MA 37740 A1 20161130; MA 37740 B2 20201028; MX 2014015743 A 20150723; MX 358323 B 20180814; MY 164536 A 20171229; NZ 702980 A 20170630; PE 20150196 A1 20150302; PH 12014502785 A1 20150202; PH 12014502785 B1 20150202; PL 2869813 T3 20190531; PL 3381444 T3 20211122; PL 3656373 T3 20220620; PL 3685826 T3 20220321; PT 2869813 T 20190227; SG 11201408261U A 20150129; SI 2869813 T1 20190430; SI 3381444 T1 20210930; SI 3656373 T1 20220630; SI 3685826 T1 20220228; TN 2014000517 A1 20160330; TW 201402152 A 20140116; TW 1632920 B 20180821; US 2014012227 A1 20140109; US 9220631 B2 20151229; WO 2014005728 A1 20140109; ZA 201409411 B 20151125

DOCDB simple family (application)

DE 202013000688 U 20130123; AR P130100235 A 20130125; AU 2013201624 A 20130125; BR 112014032990 A 20130125; BR 122020020290 A 20130125; CA 2803566 A 20130125; CH 2982013 A 20130125; CL 2014003619 A 20141231; CN 201380035900 A 20130125; CN 201910358417 A 20130125; CN 202010134846 A 20130125; CN 202110166906 A 20130125; CO 14278405 A 20141218; CY 191100225 T 20190221; CY 211100725 T 20210812; DK 13701276 T 20130125; DK 18162017 T 20130125; DK 19210117 T 20130125; DK 20159408 T 20130125; EA 201590139 A 20130125; EC PI201504005 A 20150203; EP 13701276 A 20130125; EP 18162017 A 20130125; EP 18202752 A 20130125; EP 19210117 A 20130125; EP 2013051491 W 20130125; EP 20159408 A 20130125; ES 13701276 T 20130125; ES 18162017 T 20130125; ES 19210117 T 20130125; ES 20159408 T 20130125; FR 1350671 A 20130125; GT 201400300 A 20141229; HK 14101312 A 20140212; HR P20190300 T 20190213; HR P20211216 T 20210727; HR P20220083 T 20130125; HR P20220535 T 20130125; HU E13701276 A 20130125; HU E18162017 A 20130125; HU E20159408 A 20130125; IL 23629614 A 20141215; IL 27291520 A 20200226; JO P20130026 A 20130124; JO P20200175 A 20120703; JP 2013012497 A 20130125; JP 2013266737 A 20131225;

KR 20147036866 A 20130125; KR 20207006794 A 20130125; KR 20217028012 A 20130125; KR 20217041316 A 20130125;
KR 20227014971 A 20130125; KR 20227031067 A 20130125; KR 20237000676 A 20130125; LT 13701276 T 20130125;
LT 18162017 T 20130125; LT 19210117 T 20130125; LT 20159408 T 20130125; MA 37740 A 20130125; MX 2014015743 A 20130125;
MY PI2014003426 A 20130125; NZ 70298013 A 20130125; PE 2014002573 A 20130125; PH 12014502785 A 20141211;
PL 13701276 T 20130125; PL 18162017 T 20130125; PL 19210117 T 20130125; PL 20159408 T 20130125; PT 13701276 T 20130125;
SG 11201408261U A 20130125; SI 201331357 T 20130125; SI 201331917 T 20130125; SI 201331963 T 20130125; SI 201331979 T 20130125;
TN 2014000517 A 20141212; TW 102103005 A 20130125; US 201313750352 A 20130125; ZA 201409411 A 20141211